Skip to content
drillr.ai

ABBV

AbbVie Inc.

NYSE · USHealthcareDrug Manufacturers - General
$253.38-0.44%

Price as of Jul 20, 2026

ABBV news

AbbVie Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

    SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development PR Newswire IRVINE, Calif., July 14, 2026 * SkinMedica(®) launches Regenerative Science Advisory Board to shape future innovation * Expands its state-of-the-art research and development (R&D) facility to support the next generation of science-led innovation * Debuts flagship retail experiences designed to support practice and patients' needs IRVINE, Calif., July 14, 2026 /PRNewswire

    PR Newswire ·

  2. AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities

    AbbVie Employees Across Asia Unite Through Week of Possibilities by Serving and Supporting Communities PR Newswire SINGAPORE, July 13, 2026 * 873 employees volunteered more than 3,600 hours across 7 Asian markets to support local communities. * Employees partnered with 21 community organizations, positively impacting more than 4,300 people through initiatives focused on patient support, inclusion, education and environmental sustainability. SINGAPORE, July 13, 2026 /PRNewswire/ -- AbbVie employ

    PR Newswire ·

  3. AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

    AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma PR Newswire NORTH CHICAGO, Ill., July 6, 2026 * TEPKINLY(®) (epcoritamab) plus lenalidomide and rituximab (R(2)) is the first and only bispecific-based therapy approved in Europe for the treatment of relapsed or refractory follicular lymphoma in the second-line setting, offering a chemotherapy-free option *

    PR Newswire ·

  4. A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity

    Issued on behalf of Conexeu Sciences Inc. Conexeu Sciences Inc. (NASDAQ: CNXU) opened a new research and development facility at adMare BioInnovations’ M4 Innovation Centre, expanding the home of its CXU™ regenerative tissue platform, a single technology the company is designing to scale across soft-tissue restoration markets spanning aesthetics and body contouring, wound care, and breast reconstruction. RENO, Nev., July 01, 2026 (GLOBE NEWSWIRE) -- Biotech Insider (https://www.globenewswire.c

    Globe Newswire ·

  5. AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

    AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata PR Newswire NORTH CHICAGO, Ill., June 29, 2026 * Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 24(1,2) * Upadacitinib is the first JAK inhi

    PR Newswire ·

  6. AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

    AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo PR Newswire NORTH CHICAGO, Ill., June 29, 2026 * If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease * Positive CHMP opinion is supported by data from the Phase 3 Viti-Up clinical studies, in w

    PR Newswire ·

  7. SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

    SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease PR Newswire NORTH CHICAGO, Ill., June 26, 2026 * SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis * Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg * SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for p

    PR Newswire ·

  8. AbbVie to Host Second-Quarter 2026 Earnings Conference Call

    AbbVie to Host Second-Quarter 2026 Earnings Conference Call PR Newswire NORTH CHICAGO, Ill., June 26, 2026 NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its second-quarter 2026 financial results on Friday, July 31, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com (https://edge.prnewswire.com/c/lin

    PR Newswire ·

  9. BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

    BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 PR Newswire IRVINE, Calif., June 24, 2026 * 250 Women Entrepreneurs Have Been Selected to Join a Multi-Week Skill-Building, Mentorship, and Networking Program * BOTOX(®) Cosmetic Will Award 20 Participants With $20,000 Grants Each to Help Take Their Business Dreams to the Next Level IRVINE, Calif., June 24, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today ann

    PR Newswire ·

  10. AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

    AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection PR Newswire NORTH CHICAGO, Ill., June 23, 2026 * MAVIRET(®) (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older. * The approval gives clinicians an option to initiate treatment as s

    PR Newswire ·

  11. AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

    AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis PR Newswire NORTH CHICAGO, Ill., June 23, 2026 * SKYRIZI(® )(risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis(1) * Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-b

    PR Newswire ·

  12. BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)

    BALA CYNWYD, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Apogee Therapeutics, Inc. (Nasdaq – APGE) Under the terms of the Merger Agreement, Apogee will be acquired by AbbVie (NYSE – ABBV) for $135.11 per share in cash

    Globe Newswire ·

  13. AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

    AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio PR Newswire NORTH CHICAGO, Ill. and SAN FRANCISCO and BOSTON, June 22, 2026 * Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases * Apogee's lead asset, zumilokibart (APG777), is a late-stage, half-life extended monoclonal antibody targeting IL-13, in development for patients w

    PR Newswire ·

  14. AbbVie Declares Quarterly Dividend

    AbbVie Declares Quarterly Dividend PR Newswire NORTH CHICAGO, Ill., June 18, 2026 NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable August 14, 2026, to stockholders of record at the close of business on July 15, 2026. Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Divide

    PR Newswire ·

  15. Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower

    Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower PR Newswire RENO, Nev., June 16, 2026 Issued on behalf of Conexeu Sciences Inc. A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers. RENO, Nev., June 16, 2026 /PRNewswire/ -- American News Group (https://www.ameri

    PR Newswire ·

  16. Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

    Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance PR Newswire IRVINE, Calif., June 16, 2026 * SKINVIVE by JUVÉDERM(®) is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.(1)" * This is the second FDA-approved indication for SKINVIVE by JUVÉDERM(®), which has been approved since 2023 to improve skin smoothness of the cheeks in adults.(1) IRVINE, Calif., June 16, 2026 /

    PR Newswire ·

  17. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

    AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results PR Newswire NORTH CHICAGO, Ill., June 12, 2026 NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm

    PR Newswire ·

  18. Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics

    Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics PR Newswire IRVINE, Calif., June 10, 2026 * Report says that younger adult consumers say satisfaction with their appearance impacts their mental (62%) and physical (53%) well-being.(1) IRVINE, Calif., June 10, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today announced the release of What Consumers Really Want, the latest instal

    PR Newswire ·

  19. AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

    AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 PR Newswire NORTH CHICAGO, Ill., June 8, 2026 * Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers NORTH CHICAGO, Ill., June 8, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical adva

    PR Newswire ·

  20. AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

    AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire NORTH CHICAGO, Ill., June 2, 2026 NORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbv

    PR Newswire ·